The Long View: Big Pharma Is Growing Its Own Again

Therapeutic Thursday: All In Or Play The Long Game

Watchdog Wednesday: The User Fee Deal That Skipped Dessert

Trial Tuesday: Idiopathic Pulmonary Fibrosis Waits On Its Groundhog Day

Milestone Monday: Count the Events, Not the Paperwork

The Long View: Two Ways To Do A Deal

Therapeutic Thursday: A New Neighbourhood For mRNA

Watchdog Wednesday: The Evolution Of EMA’s Real-World Evidence Policy

Trial Tuesday: The Slow Drift Out Of US Trials

The US still has the biggest market and the deepest regulatory expertise but early-stage sponsors are increasingly starting somewhere else.

Milestone Monday: In This IPO Market, $81m Is The Small One

The Long View: Sanofi Rebuilds Its Workforce Around AI, Just As It Gets Pickier About What Advances

The discovery engine now runs twice as fast. A new chief executive is culling late-stage assets and raising the Phase II bar, so the bet rides on whether faster also means better.